Browse > Article

The Clinical Significance of Cathepsin D and p53 Expression in Locally Advanced Rectal Cancer  

Kim, Jun-Sang (Departments of Radiation Oncology, College of Medicine, Chungnam National University)
Lee, Sheng-Jin (Departments of Pathology, College of Medicine, Chungnam National University)
Kim, Jin-Man (Departments of Pathology, College of Medicine, Chungnam National University)
Cho, Moon-June (Departments of Radiation Oncology, College of Medicine, Chungnam National University)
Publication Information
Radiation Oncology Journal / v.26, no.1, 2008 , pp. 56-64 More about this Journal
Abstract
Purpose: Cathepsin D(CD) is a lysosomal acid proteinase that is related to malignant progression, invasion, and a poor prognosis in several tumors. The aim of this study was to evaluate the prognostic clinical significance of CD and p53 expression in pretreatment biopsy specimens from patients with locally advanced rectal cancer who were treated with preoperative chemoradiation. Materials and Methods: Eighty-nine patients with locally advanced rectal cancer(cT3/T4 or N+) were included in this study. Preoperative chemoradiation consisted of a dose of 50.4 Gy of pelvic radiation and two concurrent cycles of administration of 5-fluorouracil and leucovorin. Surgery was performed six weeks after chemoradiation. CD and p53 expression in pretreatment formalin-fixed paraffin-embedded tumor biopsy specimens were assessed by immunohistochemical staining using a CD and p53 monoclonal antibodies. The threshold value for a positive stain in tumor tissue and stromal cells was 1+ intensity in 10% of the tumors or stromal cells, respectively. Results: Positive CD expression was found in 57(64%) of the tumors and 32(35%) of the stromal cell specimens. There was no association with CD expression of the tumor or stromal cells and patient characteristics. There was a correlation between tumor CD expression with stromal cell CD expression(p=0.01). Overexpression of p53 was not a significant prognostic factor. The 5-year overall survival(OS) and disease-free survival(DFS) rates were not different between tumor CD-negative and positive patient biopsy samples(69% vs. 65%, 60% vs. 61%, respectively). The 5-year OS rates in the tumor-negative/stromal cell-negative, tumor-negative/stromal cell-positive, tumor-positive/stromal cell-negative and tumor-positive/stromal cell-positive biopsy samples were 75%, 28%, 62%, and 73%, respectively. Stromal cell staining only without positive tumor staining demonstrated the worst overall survival prognosis for patients(p=0.013). Conclusion: Overexpression of p53 in rectal biopy tissue was not associated with prognostic significance. In the pretreatment biopsy specimens, an exclusive increase in CD expression in stromal cells without tumor expression was related to poor overall survival in patients with locally advanced rectal cancer treated with preoperative chemoradiation.
Keywords
Rectal cancer; Cathepsin D; p53; Lysosomal proteinase;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging andsphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999;44:1027-1038   DOI   ScienceOn
2 Minsky BD, Cohen AM, Enker WE, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1997;37:289-295   DOI   ScienceOn
3 Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54:403-408   DOI   ScienceOn
4 van der Stappen JW, Williams AC, Maciewicz RA, Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996;67:547-554   DOI   ScienceOn
5 Talieri M, Papadopoulou S, Scorilas A, et al. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Letters 2004;205:97-106   DOI   ScienceOn
6 Lane DP. p53, guardian of the genome. Nature 1992;358:15-16   DOI   ScienceOn
7 Berchem G, Glondu M, Gleizes M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002;21:5951-5955   DOI   ScienceOn
8 Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-444   DOI   PUBMED
9 Riley LB, Lange MK, Browne J, et al. Analysis of cathepsin D in human breast cancer: Usefulness of the processed 31 ku active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Res Treat 2000;60:173-179   DOI   ScienceOn
10 Morgan M, Koorey D, Painter D, et al. p53 and DCC immunohistochemistry in curative rectal cancer surgery. Int J Colorectal Dis 2003;18:188-195   PUBMED
11 Wu GS, Saftig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998;16:2177-2183   DOI
12 Chabowski A, Sulkowska M, Sulkowski S, Famulski W, Skrzydlewska E, Kisielewski W. Immunohistochemical evaluation of cathepsin D expression in colorectal cancer. Folia Histochem Cytobiol 2001;39:153-154
13 Theodoropoulos GE, Panoussopoulos D, Lazaris AC, Golematis BC. Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma. J Surg Oncol 1997;65:242-248   DOI   ScienceOn
14 Rochefort H, Garcia M, Glondu M, et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000;291:157-170   DOI   ScienceOn
15 Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A. Relationship between cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 1997;76:661-666   DOI   PUBMED   ScienceOn
16 Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13   DOI
17 Gallego MG, Acenero MJ, Ortege S, Delgdo AA, Cantero JL. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 2000;43:971-975   DOI   ScienceOn
18 Sebzda T, Saleh Y, Gburek J, et al. Cathepsin D expression in human colorectal cancer: relationship with tumour type and tissue differentiation grade. J Exp Ther Oncol 2005;5:145-150   PUBMED
19 Sis B, Sagol O, Kupelioglu A, et al. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004;200:379-387   DOI   ScienceOn
20 Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:29-35   DOI   ScienceOn
21 Ioachim EE, Goussia AC, Machera M, Tsianos EV, Kappas AM, Agnantis NJ. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices. Anticancer Res 1999;19:2147-2155   PUBMED
22 Choi C, Kim M, Yoo S, et al. The clinicopathological factors that determine a local recurrence of rectal cancers that have been treated with surgery and chemoradiotherapy. J Korean Soc Ther Radiol Oncol 2006;24:255-262   과학기술학회마을
23 Ikeguchi M, Fukuda K, Oka S, et al. Clinicopathological significance of cathepsin D expression in gastric adenocarcinoma. Oncology 2001;61:71-78   DOI   ScienceOn
24 Oh-e H, Tanaka S, Kitadai Y, Shimamoto F, Yoshihara M, Haruma K. Cathepsin D expression as a possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur J Cancer 2001;37:180-188   DOI   ScienceOn
25 Kanber Y, Demirbag NR, Sam AD, Aydin N. Cathepsin D expression in colorectal adenocarcinomas and adenomas. Int J Biol Markers 2002;17:165-168   DOI   PUBMED
26 Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metatasis: a protease and a ligand. APMIS 1999;107:86-95   DOI   ScienceOn
27 Chabowski A, Skrzydlewska E, Sulkowska M, et al. Cathepsin D activity in colorectal cancer. Ann Acad Med Bialostoc 2001;46:38-46
28 Ioachim E, Kitsiou E, Charalabopoulos K, et al. Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices. Int J Gynecol Cancer 2003;13:344-351   DOI   ScienceOn
29 Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998;41:585-591   DOI   ScienceOn
30 Li S, Kim JS, Kim JM, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006;65:705-712   DOI   ScienceOn
31 Talieri M, Papadopoulou S, Scorilas A, et al. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 2004;205:97-106   DOI   ScienceOn
32 Korean National Statistical Office. Annual report on the cause of death statistic in 2005. 2006
33 Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740   DOI   ScienceOn
34 Ioachim E, Charchanti A, Stavropoulos N, Athanassiou E, Bafa M, Agnantis NJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res 2002;22:3383-3388   PUBMED
35 Duffy MJ. Role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-155   DOI